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Abstract
Leptospirosis is a serious infection disease caused by pathogenic strains of the Leptospira
spirochetes, which affects not only humans but also animals. It has long been expected to find an
effective vaccine to prevent leptospirosis through immunization of high risk humans or animals.
Although some leptospirosis vaccines have been obtained, the vaccination is relatively unsuccessful
in clinical application despite decades of research and millions of dollars spent. In this review, the
recent advancements of recombinant outer membrane protein (OMP) vaccines, lipopolysaccharide
(LPS) vaccines, inactivated vaccines, attenuated vaccines and DNA vaccines against leptospirosis are
reviewed. A comparison of these vaccines may lead to development of new potential methods to
combat leptospirosis and facilitate the leptospirosis vaccine research. Moreover, a vaccine ontology
database was built for the scientists working on the leptospirosis vaccines as a starting tool.
1. Background
Leptospirosis is a widespread disease [1], caused by infec-
tion with the spirochete bacterium Leptospira, which
affects almost all mammals [1-13]. Leptospirosis was ini-
tially described as Weil's syndrome [8,14]. It is predomi-
nantly an occupational disease which affects humans who
come into frequently contact with rodents, pets or pol-
luted water [15-18] (Fig. 1). Infection is facilitated with
penetrating leptospires through mucosa or an open skin
[19]. After gaining entry through the skin, the bacterium
causes a serious disease [19]. The symptoms of leptospiro-
sis are extremely broad from meningitis [20], pneumoni-
tis [21,22], hepatitis [23], nephritis [24-27], pancreatitis
[28] and erythema nodosum [29] and death [30,31]. Fig.
2 shows the data of human leptospirosis cases reported by
Ministry of Health of the People's Republic of China from
January 2002 to October 2007 in China mainland. Dur-
ing this time, about 1,500 infected cases and 50 dead were
reported. However, many human leptospirosis cases
might be misdiagnosed or omitted due to poor medical
care and information. Leptospira has over 200 pathogenic
serovars, and divides into 25 serogroups, and many differ-
ent strains with small antigenic differences can be found
in some serovars [2,17].
Leptospires have evolved ways to escape the immune
defense. Pathogenic leptospires are able to translocate
through cell monolayers at a rate significantly greater than
that of nonpathogenic leptospires [32]. The rapid translo-
cation of pathogenic leptospires between mammalian
cells allows the bacteria to quickly reach the bloodstream
and disseminate to multiple organs [32]. Virulent lepto-
spires can rapidly enter kidney fibroblasts and induce a
programmed cell death [33]. Thus, it is a challenge for
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ospirosis vaccine [34-37]. Currently, molecular and cellu-
lar studies on leptospirosis vaccines have been focused on
bacterial motility [38,39], lipopolysaccharides (LPSs)
[10,40-47], lipoproteins [48-56], outer-membrane pro-
teins (OMPs) [52,53,57-62] and potential virulence fac-
tors [39,63-68]. However, it is still a lack of an extensive
knowledge-based annotation of leptospirosis vaccines for
the scientists working in the field of leptospirosis vaccines.
It has inspired us to investigate the current developments
of leptospirosis vaccines and to construct a database of the
leptospirosis vaccines for incorporating the leptospirosis
vaccine information into bioinformatics by using Micro-
soft SQL server technology and intelligent algorithms (see
section 6 and website [69]).
Here, we classified the leptospirosis vaccines into recom-
binant protein vaccines, lipopolysaccharide (LPS) vac-
cines, inactivated and attenuated vaccines, and DNA
vaccines for reviewing the current advancements in lept-
ospirosis vaccine research.
2. Recombinant protein vaccines
Recombinant protein vaccines have a great potential
against leptospirosis. Several leptospiral recombinant
protein vaccines have been constructed with modern bio-
technological methods [48,53,56,58,61,70-75], of which
recombinant OMPs, lipoproteins, and virulence factors
acquired a considerable interest.
2.1. Recombinant OMP vaccines
The protective characteristics of several recombinant OMP
vaccines have been tested, including leptospiral outer
membrane protein OmpL1, lipoprotein LipL41 [53],
hemolysis-associated protein 1 (Hap1) [76] and immu-
noglobulin-like (Lig) protein [77]. In 1993, the first lept-
ospiral OMP protein, a 31 kDa surface protein OmpL1 of
Leptospira, was reported [78]. 6 years later, studies on the
Golden Syrian hamster model of leptospirosis demon-
strated immunoprotective effects of the leptospiral outer
membrane protein OmpL1 and lipoprotein LipL41 [53].
However, after another 2 years, it was reported that aden-
ovirus-mediated OmpL1 failed to protect gerbils against
heterologous Leptospira infection, contrary to adenovirus-
mediated Hap1, which induced a significant protection
[76]. In 2002, a 130 kDa immunoreactive leptospiral
immunoglobulin-like protein A (LigA) from L. interrogans
was described [77]. Then, the immune response of LigA
proteins was confirmed, as two immunoglobulin-like
proteins, LigA and LigB, induced a protection against lept-
ospires [56,73,74]. These results indicated that LigA and
LigB may play an important role in the host cell attach-
ment, as well as invasion during leptospiral pathogenesis
Human leptospirosis cases in People's Republic of China dur-ing 2002–2007 n Chin  ma landFi ure 2
Human leptospirosis cases in People's Republic of China dur-
ing 2002–2007 in China mainland. The data were reported by 
the Ministry of Health of the People's Republic of China. The 
blue bars are the infected cases, and the yellow bars are the 
dead cases. The data of 2007 are the infected and dead 
human leptospirosis cases from January to October.
The infection pathway of LeptospireFigure 1
The infection pathway of Leptospire. A): Leptospires in the 
nature resource. B): Leptospires in the rodents or wield ani-
mals. C): Leptospires in pets. D): Leptospires in water or 
soil. E): The infected human can develop meningitis, pneumo-
nitis, hepatitis, pancreatitis, nephritis and erythema nodosum. 
The organisms are excreted in urine. They survive for longer 
periods in natural waters.Page 2 of 10
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the detection of pathogenic Leptospira [82].
Several leptospiral outer membrane proteins, e.g. LAg42,
Loa22, Lk73.5, have been recognized as leptospirosis vac-
cine candidates, but they were not tested in animal mod-
els for vaccine development. LAg42 is a 42 kDa inner-
membrane protein. It was identified in pathogenic Lept-
ospira as a factor involved in virulence [83]. Loa22 was
found among pathogenic leptospires but not in non-path-
ogenic leptospires. It is located in the outer membrane
and exposed on the cell surface. It has been considered as
a candidate for a novel vaccine against leptospirosis [49].
Lk73.5 is a host-inducible immunogenicity protein from
pathogenic L. interrogans [72]. Although the protective
characteristics of LAg42, Loa22 and Lk73.5 are not availa-
ble, we believe these outer membrane proteins might be
suitable as vaccine candidates.
2.2. Recombinant lipoprotein vaccines
Lipoproteins are important proteins in leptospires. These
proteins are abundant in the outer membrane, to which
they are attached through fatty acids. Because of difficulty
in production of lipoproteins in heterologous expression
systems, only LipL41 was reported as a potential vaccine.
However, many lipoproteins (for example: LipL32,
LipL45 and LipL21) could be suitable as vaccine candi-
dates. LipL32 [52] and LipL41 were identified as targets
during natural infection by leptospires [37]. They are
potentially useful for serodiagnosis and may serve as tar-
gets for vaccine design. LipL45 [67] and LipL21 [50] were
described as surface membrane lipoproteins that are pro-
duced during infection and conserved among pathogenic
Leptospira species. LipL45 is produced as a 45-kDa lipo-
protein and it is processed to a 31-kDa C-terminal form,
P31LipL45 [67]. LipL45 is also called Qlp42 [84].
Moreover, the lipoprotein-like complex glycolipoproteins
(GLPs) were suggested as vaccine candidates. A glycolipo-
protein (GLP) extracted from either pathogenic L. interro-
gans or nonpathogenic L. biflexa was shown to induce
production of the tumor necrosis factor, interleukin-10
and CD69 [85]. Obviously, the reported lipoproteins
(LipL32, LipL45, LipL21 and GLP) are leptospirosis vac-
cine candidates.
On the other hand, lipoprotein LipL36 was found not
suitable as leptospirosis vaccine. LipL36 is a 36 kDa lept-
ospiral outer membrane lipoprotein [54], which is syn-
thesized at 30°C, but not at 37°C in vivo [84,86].
Production of this protein was downregulated in host-
adapted leptospires, suggesting that it is not involved in
pathogenesis after entry into the mammalian host [62].
2.3. Recombinant virulence factor vaccines
Only a few papers were reported to identify leptospiral vir-
ulence factors, including FlaA, FlaB [87], Hsp58 [88],
SphH [89,90] and ChpK [91]. FlaA and FlaB are important
components of leptospiral periplasmic flagella (PF). PF is
a complex structure, composed of a core, surrounded by
two sheath layers, which are important virulence factors
of Leptospira [92]. In most spirochete species, the core of
PF consists of at least three proteins: FlaB1, FlaB2 and
FlaB3. The FlaA protein forms a sheath around the FlaB
core. FlaA, together with FlaB, impact PF helical morphol-
ogy [87].
Using flaA::cat, flaA::kan, flaB1::kan, flaB2::cat and
flaB3::cat mutants, it was shown that these strains were
less motile than the wild-type strain [38]. These results
indicate that FlaA and FlaB are virulence factors of Lept-
ospira. The gene encoding the FlaB virulence factor, flaB,
can be amplified from the genomic DNA of several path-
ogenic serovars. Cloning and sequence analysis indicated
that flaB is suitable in the detection of infection by patho-
genic leptospires [93].
The virulence factor Hsp58 is a major target for the vaccine
design [88]. The virulence factor hemolysin SphH is a
pore-forming protein on several mammalian cells. The
immune serum against the full-length hemolysin can
effectively neutralize the SphH-mediated hemolytic and
cytotoxic activities. SphH is required for pore formation in
mammalian cell membranes and cytotoxic activities to
mammalian cells [89,90]. The virulence factor ChpK is
encoded by L. interrogans chp locus, which consists of two
genes: chpK and chpI. Expression of chpK in Escherichia coli
results in inhibition of bacterial growth. Coexpression of
chpI neutralizes ChpK toxicity. The chp locus was found in
all representative pathogenic strains of L. interrogans [91].
All virulence factors described above (Hsp58, FlaA, FlaB,
SphH and ChpK) can be considered as candidates for lept-
ospirosis vaccines.
Only Lig, LipL41 and Hap1 proteins were approved as
vaccines against Leptospira in animals. Many recently
reported outer membrane proteins (LAg42, Loa22,
Lk73.5), lipoproteins (LipL32, LipL45, LipL21 and GLP)
and newly discovered virulence factors (Hsp58, FlaA,
FlaB, SphH and ChpK) can help us to find more suitable
vaccine candidates [1-4,8,9,11-13,94]. Because the
genomes of L. interrogans serovar Icterohaemorrhagiae Lai
[63] and L. interrogans serovar Copenhageni [95] were
reported, heterologous expression of leptospiral outer
membrane proteins (OMPs) became possible and opened
new possibilities for vaccine development [10]. The basic
rout of large-scale screening of the leptospirosis vaccines
is shown in Fig. 3. Before recombinant protein vaccines
against leptospirosis can be used for clinical application,Page 3 of 10
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cines must be free of contaminations, they should be sta-
ble and safe, and easy to transport and store.
3. LPS vaccines
Analysis of LPSs should open new avenues for vaccine
developments [10,66]. The synthesis of LPSs in Leptospira
is similar to that in other Gram-negative bacteria [42,96-
98]. Leptospiral LPSs activate macrophages through CD14
and the Toll-like receptor 2 (TLR2) [40,99,100]. It is LPS,
not lipoprotein, that stimulates the signaling component
for macrophages through the TLR2 pathway [99]. Many
reports have been published on leptospiral LPSs as vac-
cine candidates against leptospirosis [43-47,101-103].
It has been found that a LPS vaccine may be serovar-inde-
pendent. For example, LPS vaccine prepared from L. bifl-
exa serovar Patoc can effectively protect hamsters against
L. interrogans serovar Manilae. In this case, the protective
effect strongly depended on the dose and administration
times of LPS vaccine prepared from L. biflexa serovar Patoc
[104]. However, it was also reported that a LPS vaccine
can be serovar-dependent; for example, LPS vaccines pre-
pared from several different serovar strains could not
induce a protective immune response in gerbils against
the strains of different serovars [105]. Obviously, further
studies are required to determine whether other LPS vac-
cines are serovar-dependent or -independent. If LPS vac-
cines are serovar-independent in different animals or
human, it will make LPS vaccines more simple and effi-
cient.
In 1989, a pioneer research on leptospiral LPS vaccines
was reported [44]. Immunization characteristics of LPSs
and polysaccharide (PS) in hamsters were compared.
When hamsters were immunized with leptospiral LPSs or
Large-scale screening of the leptospirosis vaccinesFigure 3
Large-scale screening of the leptospirosis vaccines. A): The screening experiment is started from the Leptospira genome 
sequence, B): Putative outer membrane protein genes are cloned into expression vector for recombinant protein production. 
C): Vaccination experiments are performed in an animal model. D): Selected vaccines are applied to human for clinical applica-
tion testing.Page 4 of 10
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imum titers were observed approximately 6 weeks after
immunization. The protection was achieved by immuni-
zation with as little as 2.5 μg of LPS or PS [44]. The
immune characteristics of LPS were compared with PS
and immunoconjugate of PS and diphtheria toxoid (DT)
in mice vaccinated with these compounds. The maximum
agglutinin titers could be achieved at 6–10 weeks after
vaccination with LPS or PS-DT conjugate. PS-DT gave anti-
body titers at least 10 times higher than those produced in
response to LPS. Titers obtained in experiments with anti-
gens of serovar Pomona were higher than those of serovar
Hardjo [43]. The protective ability of LPS extracts were
compared with the protein extracts in experiments in
which leptospirosis was induced in gerbils [105]. Total
extracts induced complete protection against homologous
infections and partial protection against heterologous
infections. LPS fractions only protected against homolo-
gous but not heterologous infections, whereas protein
extracts caused a significant protection against both types
of infections [105].
Moreover, an immunogenicity of oligosaccharide fraction
from the LPS of L. interrogans serovar Pomona was
reported [102]. The oligosaccharide was isolated by endo-
glycosidase H digestion and column chromatography
purification. When conjugated to diphtheria toxoid, the
oligosaccharide caused production of a significant
amount of protective antibodies [102].
Several lipopolysaccharide-like substances (LSSs) were
reported as Leptospira antigens [47,106,107]. LSS was
extracted from L. interrogans with a chloroform-methanol-
water solution and partially purified by silica gel column
chromatography. This antigen exhibited a protective activ-
ity in hamsters infected with lethal doses of L. interrogans
[106,107]. Moreover, LLS extracted from L. interrogans by
the hot phenol-water method could enhance the immu-
nological response in vivo [47].
Since LPSs are major antigens involved in serological
response [45], these molecules can be considered as can-
didates for serodiagnosis [41]. For example, although L.
borgpetersenii subtype Hardjobovis and L. interrogans sub-
type Hardjoprajitno belong to different species, they are
serologically indistinguishable, and thus classified as sero-
var Hardjo. This is because the LPSs of these subtypes are
identical [103]. Hence, LPSs can be used not only as lept-
ospirosis vaccines, but also as antigens for serodiagnos-
tics.
Although LPSs have been tested as leptospirosis vaccines
for almost 20 years, and promising results have been
obtained, there are still have many problems to be solved.
Between others, details of compositions and structures of
leptospiral LPSs have to be determined.
4. Inactivated and attenuated vaccines
The inactivated and attenuated vaccines have been
reported for more than 50 years. Some inactivated or
attenuated leptospirosis vaccines were successfully tested
in cattle [108-116] and dog [7,27,117-122]. Inactivated
leptospirosis vaccines were also tested in human volun-
teers [12,123-126]. The sera from persons vaccinated with
a bivalent whole cell inactivated vaccine of L. interrogans
serovar Hardjo or serovar Pomona contained IgM specific
to both serovars [125]. Although the only leptospirosis
vaccine licensed for humans is being produced in Cuba
since 2006, inactivated and attenuated vaccines still
acquire considerable interests. They are especially suitable
as veterinary vaccines. When dogs were vaccinated twice
with such vaccines and infection with L. interrogans fol-
lowed the second vaccination, a high rate of protection
against L. interrogans was observed and duration of immu-
nity was at least 1-year [127]. The efficiency of inactivated
vaccine could be improved by adjuvant and vaccination
frequency. A commercial inactivated leptospirosis vaccine
(with adjuvant) induced a poor antibody production in
cattle during preliminary vaccination. However, after
booster vaccination, this vaccine caused a remarkable
immune response [128]. Hydrostatic pressure-treated
leptospires can be used as inactivated vaccine. After such
leptospires were inoculated into rabbits, the vaccine was
immunogenic [129]. The inactivated vaccine can induce a
strong antigen-specific proliferative response by periph-
eral blood mononuclear cells (PBMC) of vaccinated cattle
2 months after the first dose of vaccine [130].
The results discussed above show that inactivated or atten-
uated vaccines are suitable as the leptospirosis vaccines
[4,5,8-11,13]. However, such vaccines cause safety prob-
lems [131,132].
5. DNA vaccines
DNA vaccines have been used against different diseases
[133]. These vaccines have several advantages over recom-
binant protein vaccines. Namely, DNA vaccines have very
simple processing routes [134,135], low prices [136], and
easy administration properties [137,138]. In just a few
years, DNA vaccine technology has been developed from
an interesting observation to the practical application
[139-141]. Surprisingly, only two leptospiral DNA vac-
cine trials have been reported. DNA vaccine encoding
hemolysis-associated protein 1 (Hap1) was tested in ger-
bils, and partial protection against the infection by patho-
genic strains of Leptospira was achieved [142]. Another
example is the use of a DNA vaccine containing the endo-
flagellin gene flaB2 in experiments with guinea pigs [143].
Obviously, leptospirosis DNA vaccines need more exten-Page 5 of 10
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immune characteristics of multiple leptospirosis DNA
vaccine complexes in animals.
6. Leptospirosis vaccine ontology database
With the development of leptospirosis vaccines, it is now
possible to construct a database for leptospirosis vaccines.
We have constructed a leptospirosis vaccine ontology
database, which is available at the website [69]. In this
database, we have presented information on some impor-
tant leptospirosis vaccines. Each vaccine in the database
has an ontology value, obtained on the basis of the exper-
imental results from particular report and expert evalua-
tion. We believe that this database may be helpful for
scientists working in the leptospirosis field, as well as for
those working on bioinformatics. The information on
vaccines can be transmitted to the bioinformatics field for
vaccine classification, processing optimization and pre-
dicting of vaccine efficiency from amino acid sequences or
compositions without experiments on animals.
7. Future developments in leptospirosis vaccine
Vaccines are administered to a large number of healthy
humans and animals to make them resistant to diseases,
therefore, vaccines must be of high safety [144,145]. There
are two basic types of leptospirosis vaccines available,
attenuated and inactivated leptospirosis vaccines. How-
ever, these two types of vaccines reveal significant safety
problems.
The attenuated vaccines were achieved by propagation of
the microbe under conditions different from those in the
infected host and, hopefully, unfavorable to its growth in
the host. Obviously, this method could not guarantee
enough safety. It requires many tests to ensure the safety,
but the safety still remains an issue. A more rational
approach to attenuate the microbe would be to inactivate
leptospiral components or genes known to code virulence
factors. For example, an attenuated leptospiral vaccine
could be developed by elimination of the leptospiral O
antigen. Analogously, inactivation of the LPS biosynthetic
loci (rfb) might result in attenuation a leptospiral strain.
Careful analysis of genes coding for the virulence factors
of Leptospira should allow us to construct attenuated
strains for leptospirosis vaccines.
Inactivated leptospirosis vaccines were extensively investi-
gated during 70–80s' of 20th century. The major problems
concerned both their safety and efficacy. It appears that a
combination of attenuated and inactivated leptospirosis
vaccine may be highly effective. New attenuated vaccines
should be designed on the basis of our knowledge about
sequences of genomes and virulence determinants of the
pathogens to maximize their safety.
A real breakthrough for leptospirosis vaccines was the
genetic technology that allows expression of leptospiral
genes in heterologous organisms. In fact, many outer
membrane proteins have been obtained, which are candi-
dates for vaccines [58]. The advantages of production of
recombinant vaccine antigens in a selected heterologous
host organism arises from simplicities of cultivation of the
host and purification of recombinant proteins. Further-
more, recombinant proteins are useful as antigens in
immunoassays to detect leptospires.
It has been reported that leptospirosis vaccines with adju-
vant were more immunogenic than those without adju-
vant [146]. Thus, it appears that more research is required
to develop novel adjuvants for leptospirosis vaccines, like
recently described bacterial tRNA adjuvant [147] and
cdiGMP adjuvant [140].
Increasing attention is being devoted to the fact that infec-
tions of leptospires are naturally acquired through
mucosa. Administering the vaccines by the mucosal route
[148-152], oral route [153-156], nasal spray [157], or
through topical application on the skin would be wel-
come [138]. The optimal formulations, adjuvants, doses
and schedules are crucial for vaccine efficacy [127,158].
The idea to produce leptospiral antigens as protein com-
ponents of edible plants is indeed feasible, and the idea of
the combination of leptospirosis vaccines and drugs to
cure leptospirosis is very interesting [6,8,9,158]. An
improvement of quality of DNA vaccines and recom-
binant protein vaccines appears to be important for the
practical application [135,159-161]. Moreover, we believe
that construction of a web service, like the leptospirosis
vaccine ontology database, would be important for scien-
tists working on leptospirosis vaccines.
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